Literature DB >> 1861141

Binding of botulinum and tetanus neurotoxins to ganglioside GT1b and derivatives thereof.

C L Schengrund1, B R DasGupta, N J Ringler.   

Abstract

The ability of fragments derived from botulinum neurotoxin (BTx) serotype A to bind to GT1b-coated plastic wells was investigated and compared with the binding characteristics of the parent approximately 150-kDa protein. Although the approximately 50-kDa light chain of BTxA had a marginal binding capacity, the predominant adherence to GT1b-coated wells was exhibited by the approximately 50-kDa carboxy-terminal half of the approximately 100-kDa heavy chain of BTxA; the amino-terminal half of the heavy chain lacked the ability to bind. Binding to GT1b by BTxA and its fragments was compared with that of tetanus neurotoxin (TTx) and the carboxy-terminal half of its heavy chain. Binding of BTxA and the C-terminal half of the heavy chain was optimal in buffers of low ionic strength (mu less than or equal to 0.04 and 0.06, respectively), whereas the heavy chain bound GT1b best at mu greater than or equal to 0.10. TTx and the approximately 50-kDa C-terminal half of its approximately 100-kDa heavy chain bound GT1b at ionic strengths similar to those of BTxA. Comparison of the binding of BTx serotypes A, B, and E to GT1b (using conditions that were found to be optimal for binding by BTxA) indicated differences in the interaction of the three serotypes with GT1b. Compared with BTxA, adherence to GT1b by serotypes B and E was reduced by approximately 60 and approximately 90%, respectively.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1861141     DOI: 10.1111/j.1471-4159.1991.tb08253.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  10 in total

1.  Comparative in vitro and in vivo assessment of toxin neutralization by anti-tetanus toxin monoclonal antibodies.

Authors:  Mehdi Yousefi; Roya Khosravi-Eghbal; Ahmad Reza Mahmoudi; Mahmood Jeddi-Tehrani; Hodjatallah Rabbani; Fazel Shokri
Journal:  Hum Vaccin Immunother       Date:  2013-10-14       Impact factor: 3.452

Review 2.  Properties and use of botulinum toxin and other microbial neurotoxins in medicine.

Authors:  E J Schantz; E A Johnson
Journal:  Microbiol Rev       Date:  1992-03

3.  Uptake of exogenous gangliosides by rat brain synaptosomes.

Authors:  H P Young; Z F Christian; R Cabeza; L N Irwin
Journal:  Neurochem Res       Date:  1998-12       Impact factor: 3.996

Review 4.  Glycosphingolipids-sweets for botulinum neurotoxin.

Authors:  Brian C Yowler; Cara-Lynne Schengrund
Journal:  Glycoconj J       Date:  2004       Impact factor: 2.916

5.  Binding of botulinum neurotoxin to pure cholinergic nerve terminals isolated from the electric organ of Torpedo.

Authors:  J Blasi; G Egea; M J Castiella; M Arribas; C Solsona; P J Richardson; J Marsal
Journal:  J Neural Transm Gen Sect       Date:  1992

6.  Pepsin fragmentation of botulinum type E neurotoxin: isolation and characterization of 112, 48, 46, and 16 kD fragments.

Authors:  J A Giménez; B R DasGupta
Journal:  J Protein Chem       Date:  1992-06

7.  Botulinum neurotoxin type A: structure and interaction with the micellar concentration of SDS determined by FT-IR spectroscopy.

Authors:  B R Singh; M P Fuller; B R DasGupta
Journal:  J Protein Chem       Date:  1991-12

Review 8.  Protein Toxins That Utilize Gangliosides as Host Receptors.

Authors:  Madison Zuverink; Joseph T Barbieri
Journal:  Prog Mol Biol Transl Sci       Date:  2018-03-17       Impact factor: 3.622

9.  Oligosaccharide-derivatized dendrimers: defined multivalent inhibitors of the adherence of the cholera toxin B subunit and the heat labile enterotoxin of E. coli to GM1.

Authors:  J P Thompson; C L Schengrund
Journal:  Glycoconj J       Date:  1997-11       Impact factor: 2.916

10.  Resolution of Two Steps in Botulinum Neurotoxin Serotype A1 Light Chain Localization to the Intracellular Plasma Membrane.

Authors:  Alexander Gardner; William H Tepp; Marite Bradshaw; Joseph T Barbieri; Sabine Pellett
Journal:  Int J Mol Sci       Date:  2021-10-15       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.